Secondary Hormone Therapy for Castration-Resistant Prostate Cancer

被引：0
|
作者：
Taplin, Mary-Ellen [1 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
ONCOLOGY-NEW YORK | 2013年 / 27卷 / 05期
关键词：
INCREASED SURVIVAL; ANDROGEN RECEPTOR; ABIRATERONE; CHEMOTHERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：371 / +
页数：3
相关论文
共 50 条
  • [1] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [2] Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
    Saad, Fred
    Fizazi, Karim
    UROLOGY, 2015, 86 (05) : 852 - 861
  • [3] Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer
    Ponholzer, Anton
    Loidl, Wolfgang
    Bektic, Jasmin
    Dorfinger, Karl
    Hruby, Stephan
    Jeschke, Klaus
    Kramer, Gero
    Krause, Steffen
    Ludvik, Georg
    Remzi, Mesut
    Roider, Michael
    Stoiber, Franz
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (3-4) : 156 - 163
  • [4] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
  • [5] How should hormone therapy for castration-resistant prostate cancer be continued?
    Spahn, M.
    Krebs, M.
    UROLOGE, 2012, 51 (01): : 15 - +
  • [6] New therapy concepts for castration-resistant prostate cancer. Between hormone manipulation, targeted therapy and chemotherapy
    Kuebler, H.
    Miller, K.
    UROLOGE, 2013, 52 (11): : 1517 - +
  • [7] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [8] Therapy selection for metastasized castration-resistant prostate cancer
    von Amsberg, G.
    Steuber, T.
    Lorch, A.
    ONKOLOGE, 2015, 21 (09): : 825 - +
  • [9] The possibilities and mechanisms of action of hormone therapy for castration-resistant prostate cancer
    Alekseev, B. Ya.
    Andrianov, A. N.
    ONKOUROLOGIYA, 2013, 9 (01): : 68 - 73
  • [10] New therapy concepts for castration-resistant prostate cancer. Between hormone manipulation, targeted therapy and chemotherapy
    Kuebler, H.
    Miller, K.
    UROLOGE, 2013, 52 (11): : 1517 - +
12345